PE Firms in Race for GlaxoSmithKline Products

Private equity firms including Advent International, Cinven and Warburg Pincus are considering bids for a group of GlaxoSmithKline's non-prescription products, Reuters reported. Up for sale are several over-the-counter drugs including painkillers and vitamin supplements. The products have sales of around 500 million pounds ($817 million), representing about 10% of the company's total consumer healthcare business, Reuters reported.

DealsNorth AmericaUSBriefs